The effect of different proportions of astragaloside and curcumin on DM model of mice

Abstract

This paper aims to study the effects of different proportion of astragaloside and curcumin on STZ induced Diabetes Mellitus (DM) model of mice, and to select a better proportion of active components. Its ultimate purpose is to lay a basis for the follow-up research on astragaloside-curcumin capsule. Increase-decrease baseline geometric proportion design method and comprehensive performance evaluation utilised to study the effect of different proportion of astragaloside and curcumin on DM mice models, which have an intravenous tail injection of STZ. The proportions of the two components are 10:0, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 0:10 respectively. And we will screen out the optimal composition. Blood glycated serum protein (GSP), hepatic glycogen and insulin tested to observe pathological changes in the pancreas. The mice DM model was copied successfully. Compared with the model group, groups treated with the metformin and with different proportions of astragaloside and curcumin help lower the blood glucose levels and GSP levels, increase glycogen stores of model mice by different degrees, and avoid pathological changes of pancreas in the model mice. The ratio of 3:7 was selected as the optimal one, based on the comprehensive performance evaluation method, followed by the ratio of 4:6. The optimal proportion of DM models is 3:7, followed by 4:6. The ratio of total astragaloside and curcumin can lower blood glucose levels, GSP levels, promote the formation of glycogen, and improve the pathological changes of pancreas in the model mice.

<p>Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases</p>

“…AS-IV significantly increases the content of hepatic glycogen and insulin, decreases the content of blood glucose glycated serum protein, and significantly improves pancreatic pathological changes in streptozotocin-induced diabetic mice. 99 By downregulating the expression of IL-6 and TNF-α and inhibiting the NLRP3 inflammasome in the pancreas of gestational diabetic mice, AS-IV can reduce glucose and insulin levels in gestational diabetic mice. 100 Moreover, it can inhibit the expression of integrin-linked kinases in diabetic rats and restore the expression of integrin α3β1 to reduce diabetic nephropathy.…”

Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats

“…When considered in the context of the results of previous studies, our findings suggest that astragaloside IV could ameliorate hyperglycemia through multiple pathways (e.g., IKK/IjBa and IRS/AKT pathways) and alleviate hyperlipidemia through mediation of blood lipid metabolism-related enzymes (e.g., Akt-dependent phosphodiesterase 3B). [17][18][19]21 Oxidative stress is a major pathological process associated with an increased risk of cardiovascular disease in DM patients, and astragaloside IV comprises a promising regulatory treatment that may reduce damage caused by oxidative stress in various conditions. 7,22 A previous in vitro experiment revealed that astragaloside IV can protect apolipoprotein E-deficient mice from cardiac remodeling through the regulation of multiple pathways and pathological processes, including the reduction of oxidative stress through reversal of oxidantantioxidant effects in heart tissue.…”

“…When considered in the context of the results of previous studies, our findings suggest that astragaloside IV could ameliorate hyperglycemia through multiple pathways (e.g., IKK/IκBα and IRS/AKT pathways) and alleviate hyperlipidemia through mediation of blood lipid metabolism-related enzymes (e.g., Akt-dependent phosphodiesterase 3B). 17 – 19 , 21 …”

Inhibition of Aortic Intimal Hyperplasia and Vascular Smooth Muscle Proliferation and Extracellular Matrix Protein Expressions by Astragalus–Angelica Combination

“…The baseline geometric design method [ 17 ] was used and the baseline combination of Astragalus–Angelica was set at 5:1, and the Astragalus and Angelica dosage was increased or decreased by 16.6% on both sides in order to design different combinations of Astragalus–Angelica, in addition with the positive drug atorvastatin group (10 mg/kg). Sprague–Dawley rats were randomly divided into normal group (the left common carotid artery was exposed and ligated, but the balloon was not used), model group (the model was given normal saline with the same volume of the drug group by intragastric administration), Astragalus and Angelica with single use or different ratios groups, and atorvastatin group.…”